Introduction
Alex Zhavoronkov, PhD, Chairman and CEO of Insilico Medicine, discusses how generative AI is transforming and accelerating drug discovery, particularly for diseases related to aging. He also shares exciting news about Insilico Medicine's latest deal with Exelixis to develop novel drugs for BRCA-mutant tumors found in breast, ovarian, pancreatic and prostate cancers.